Your browser doesn't support javascript.
loading
Chrysin prevents inflammation-coinciding liver steatosis via AMPK signalling.
Gao, Chuanyue; Zhang, Huan; Nie, Lulin; He, Kaiwu; Li, Peimao; Wang, Xingxing; Zhang, Zaijun; Xie, Yongmei; Li, Shupeng; Liu, Gongping; Huang, Xinfeng; Deng, Huiping; Liu, Jianjun; Yang, Xifei.
Afiliação
  • Gao C; School of Public Health, Shanxi Medical University, Taiyuan, China.
  • Zhang H; Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
  • Nie L; Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
  • He K; School of Public Health, University of South China, Hunan Hengyang, China.
  • Li P; Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
  • Wang X; Institute of New Drug Research and Guangzhou, Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China.
  • Zhang Z; Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
  • Xie Y; Medical Laboratory, Shenzhen Prevention and Treatment Center for Occupational Diseases, Luohu District, Shenzhen, China.
  • Li S; School of Public Health, Shanxi Medical University, Taiyuan, China.
  • Liu G; Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
  • Huang X; Jinan Univ Coll Pharm Inst New Drug Res & Guangzhou Key Lab Innovat Chem Drug Res Cardio Cerebrovasc, Guangzhou, China.
  • Deng H; State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
  • Liu J; State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.
  • Yang X; Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Pharm Pharmacol ; 75(8): 1086-1099, 2023 Aug 01.
Article em En | MEDLINE | ID: mdl-37167529
ABSTRACT

OBJECTIVES:

We aimed to elucidate the therapeutic potential of Chrysin (CN) against the high-fat diet (HFD) induced non-alcoholic fatty liver disease (NAFLD) and its mechanism.

METHODS:

To assess the hypothesis, NAFLD was induced in C57BL/6 mice by feeding a high-fat diet for up to two months, followed by CN administration (for three months). Liver injury/toxicity, lipid deposition, inflammation and fibrosis were detected via molecular and biochemical analysis, including blood chemistry, immunoimaging and immunoblotting. Moreover, we performed proteomic analysis to illuminate Chrysin's therapeutic effects further. KEY

FINDINGS:

CN treatment significantly reduced liver-fat accumulation and inflammation, ultimately improving obesity and liver injury in NAFLD mice. Proteomic analysis showed that CN modified the protein expression profiles in the liver, particularly improving the expression of proteins related to energy, metabolism and inflammation. Mechanistically, CN treatment increased AMP-activated protein and phosphorylated CoA (P-ACC). Concurrently, it reduced inflammation and inflammation activation by inhibiting NLRP3 expression.

CONCLUSIONS:

In summary, CN treatment reduced lipid metabolism by AMPK and inflammasome activation by NLRP3 inhibition, ultimately improving NAFLD progression. These findings suggest that CN could be a potential treatment candidate for the NFLAD condition.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2023 Tipo de documento: Article